Last reviewed · How we verify
Melphalan and bortezomib — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Melphalan and bortezomib (Melphalan and bortezomib) — Dartmouth-Hitchcock Medical Center.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Melphalan and bortezomib TARGET | Melphalan and bortezomib | Dartmouth-Hitchcock Medical Center | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Melphalan and bortezomib CI watch — RSS
- Melphalan and bortezomib CI watch — Atom
- Melphalan and bortezomib CI watch — JSON
- Melphalan and bortezomib alone — RSS
Cite this brief
Drug Landscape (2026). Melphalan and bortezomib — Competitive Intelligence Brief. https://druglandscape.com/ci/melphalan-and-bortezomib. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab